drugset / Trial / NCT03381170
An Extension of the TG1101-RMS201 Trial
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Timeline
- Start
- 2017-06-01
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |